Hua Med­i­cine plans to join trendy Hong Kong IPO club, pitch­ing an of­fer­ing of up to $400M -- re­ports

A di­a­betes drug mak­er that has at­tract­ed in­vest­ment from Arch Ven­ture Part­ners, Ven­rock and WuXi AppTec is the lat­est Chi­nese com­pa­ny plan­ning an IPO in Hong Kong.

Hua Med­i­cine is ex­pect­ing to raise $300 mil­lion to $400 mil­lion in the pub­lic of­fer­ing, ac­cord­ing to Bloomberg and Reuters, which both re­port­ed the news but cit­ed dif­fer­ent num­bers. Reuters added that this will hap­pen in the sec­ond half of 2018.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.